Efficacy of paroxetine on longitudinal ADL and QOL in post-stroke depression

帕罗西汀对卒中后抑郁症纵向 ADL 和 QOL 的疗效

• 批准号: 20700455
• 负责人: TAKAHASHI Masanori
• 金额: $ 1.25万
• 依托单位: University of Occupational and Environmental Health, Japan
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20700455/
• 关键词: 脳卒中後うつ(PSD); 塩酸パロキセチン; ADL; QOL; 脳卒中後うつ

We administered paroxetine, one of the selective serotonin reuptake inhibitor (SSRI), or nicergoline as a control to patients with post-stroke depression (PSD) for eight weeks and evaluated the severity of depression, disabilities of stroke and QOL for eight months. The severity of depression was improved at the group which administered paroxetine during a medicine dosage period in comparison with the control group, but did not recognize a difference in ability of gait and ADL at the time of the medicine dosage end. However, it was the tendency that the hospitalization came to shorten in the group which administered paroxetine. The dosage of the SSRI for PSD did not affect longitudinal ADL and QOL. But it improves depression early to diagnose as PSD and administer SSRI, and it may shorten hospitalization.

以选择性5-羟色胺再摄取抑制剂(SSRI)帕罗西汀或尼麦角林为对照，对卒中后抑郁(PSD)患者进行为期8周的抑郁程度、卒中残疾和生活质量评估。与对照组相比，在给药期间给予帕罗西汀的抑郁程度有所改善，但在给药结束时未发现步态能力和日常生活活动能力的差异。而帕罗西汀组的住院时间有缩短的趋势。SSRI治疗PSD的剂量不影响纵向ADL和生活质量。但它可以改善抑郁症的早期诊断为PSD和实施SSRI，并可能缩短住院时间。